GLPwatch
Does Personality Predict Patient Adherence, Health Behaviors, and Weight Loss Outcomes During the Latino Crossover Semaglutide Study (LCSS)? (Story-LCSS Project)
NCT05622045 · Active, not recruiting
Last updated 2026-05-28This clinical trial is studying whether personality traits can help predict how well Latino patients will follow their treatment plan, adopt healthy habits, and lose weight while taking semaglutide.
What this study is testing ClinicalTrials.gov NCT05622045 ↗
Description as written by the study sponsor.
The goal of this observational study is to learn about the personality attributes and values of people living with obesity that are part of the Latino community, and how these personality attributes and values can help to predict success during a weight loss program. The main questions it aims to answer are: * What are the personality attributes and values of people living with obesity that sign up to the LCSS-Latino Crossover Semaglutide Study trial? * Can behavioral artificial intelligence (a computer formula) predict which patients will complete the LCSS-Latino Crossover Semaglutide Study trial? * How do behavioral artificial Intelligence predictions (a computer formula) compare to clinician predictions of patient success? * Can behavioral artificial intelligence (a computer formula) predict patient weight loss, calorie consumption and physical activity levels during the LCSS-Latino Crossover Semaglutide Study trial? Participants will be recorded in English and Spanish while responding to a question regarding participation in a weight loss study.
Treatments tested
- Voice data Behavioral
Recorded response to a question about their participation in a weight loss study.
| Main thing measured | Predicted patient weight change success |
|---|---|
| Sponsor | Loma Linda University |
| Conditions studied | Obesity, Body Weight Changes |
| GLP-1 drugs | semaglutide |
Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT05622045 ↗